Dr. Wael Sumaya MD, MRCP, PhD
NIHR Clinical Lecturer in Cardiology
Department of Infection, Immunity and Cardiovascular Disease
University of Sheffield
Beech Hill Road
Tel: +44 (0) 114 305 2019
I joined the University of Sheffield as an Academic Clinical Fellow in 2010. During this period, I started training in clinical cardiology and developed a keen interest in atherothrombosis research. Subsequently, I was awarded a BHF-funded clinical research training fellowship to continue my research with Professor Rob Storey. During this work, I identified poor fibrinolysis as an independent predictor of poor outcomes following acute coronary syndrome, which may constitute a novel therapeutic target. For this work, I was awarded my PhD. I am currently a NIHR Clinical Lecturer in Cardiology. I am also an honorary specialist registrar in Cardiology. As a clinician, I enjoy interventional treatment of patients with coronary artery disease and as a researcher, I look for ways to optimise antithrombotic regimens.
My research interests are:
- Fibrin clot lysis and risk following ACS.
- Mechanisms implicated in poor lysis following ACS.
- Antithrombotic therapy in patients with coronary artery disease.
I am deputy cardiovascular module co-ordinator for phase 1 medical students. I also enjoy delivering lectures regularly to medical students, post graduate students and junior doctors.
- Fellow Editor for the British Cardiovascular Intervention Society.
- Member of the British Cardiovascular Intervention Society.
- Member of the Royal College of Physicians.
- Prolonged enoxaparin in primary percutaneous coronary intervention (MRC Confidence in Concept Project).
- Fibrin clot properties and clinical outcomes following acute coronary syndromes (BHF Clinical Research Training Fellowship).
For key publications see below. For a full list of publications click here.
- Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?. Thrombosis and Haemostasis. View this article in WRRO
- Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets, 30(2), 148-157. View this article in WRRO
- Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). Circulation, 138(13), 1290-1300. View this article in WRRO
- Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study). Thrombosis and Haemostasis, 118(07), 1250-1256. View this article in WRRO
- Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: A PLATO substudy. European Heart Journal, 39(13), 1078-1085. View this article in WRRO
- The challenges of antithrombotic therapy in patients with left ventricular thrombosis. European Heart Journal, 39(3), 209-211.
- Ticagrelor: Effects Beyond the P2Y12 Receptor.. Interv Cardiol Clin, 6(1), 49-55. View this article in WRRO
- Stability of VerifyNow P2Y12 assay results with citrate anticoagulation as compared to hirudin anticoagulation over 20-min period. Platelets, 26(3), 271-273.
- Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting. EuroIntervention, 9(1), 62-69.
- Hirudin anticoagulation allows more rapid determination of P2Y12 inhibition by the VerifyNow P2Y12 assay. Thrombosis and Haemostasis, 109(03), 550-555.